Fredag 1 Maj | 19:53:07 Europe / Stockholm

Kalender

Est. tid*
2026-07-28 18:00 Kvartalsrapport 2026-Q2
2026-05-05 N/A X-dag ordinarie utdelning EL 4.00 EUR
2026-04-28 - Extra Bolagsstämma
2026-04-28 - Årsstämma
2026-02-11 - Bokslutskommuniké 2025
2025-07-28 - Kvartalsrapport 2025-Q2
2025-05-07 - X-dag ordinarie utdelning EL 3.95 EUR
2025-04-30 - Årsstämma
2025-04-30 - Extra Bolagsstämma
2025-02-12 - Bokslutskommuniké 2024
2024-07-25 - Kvartalsrapport 2024-Q2
2024-05-03 - X-dag ordinarie utdelning EL 3.95 EUR
2024-04-30 - Extra Bolagsstämma
2024-04-30 - Årsstämma
2024-02-14 - Bokslutskommuniké 2023
2023-07-26 - Kvartalsrapport 2023-Q2
2023-05-22 - X-dag ordinarie utdelning EL 3.23 EUR
2023-05-17 - Extra Bolagsstämma
2023-05-17 - Årsstämma
2023-03-10 - Bokslutskommuniké 2022
2022-07-29 - Kvartalsrapport 2022-Q2
2022-05-30 - X-dag ordinarie utdelning EL 2.51 EUR
2022-05-25 - Extra Bolagsstämma
2022-05-25 - Årsstämma
2022-03-11 - Bokslutskommuniké 2021
2021-07-30 - Kvartalsrapport 2021-Q2
2021-05-28 - X-dag halvårsutdelning EL 1.08
2021-05-21 - Extra Bolagsstämma
2021-05-21 - Årsstämma
2021-03-12 - Bokslutskommuniké 2020
2020-12-23 - X-dag bonusutdelning EL 1.15
2020-06-25 - Extra Bolagsstämma
2020-06-25 - Årsstämma
2019-10-30 - Kvartalsrapport 2019-Q3

Beskrivning

LandFrankrike
SektorHandel & varor
IndustriDetaljhandel
EssilorLuxottica är specialiserat inom tillverkning och design av linser. Inom koncernen återfinns ett flertal varumärken, där de mer kända inkluderar Crizal, Varilux samt Essilor. Utöver erbjuds även helhetslösningar med ramar och glasögon för personligt bruk, men även för industriell användning. Verksamhet innehas på global nivå, huvudsakligen runtom Nordamerika och Europa, med privata kunder som dominerande kundbas.

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-04-22 18:00:00

Revenue rising 10.8% in Q1

Third consecutive quarter of double-digit growth

  • Group revenue at Euro 7,127 million in Q1, up 10.8% at constant exchange rates1 and +4.1% at current rates
  • Both Professional Solutions and Direct to Consumer growing double digits
  • Traditional business running at mid-single-digit pace
  • North America up 12.5% and EMEA up 9.5%, supported by AI glasses and strong Ray-Ban brand performance
  • China accelerating, up low teens supported by myopia and retail
  • Myopia management portfolio growing 26%, with the key market of China up 18%
  • AI glasses new Ray-Ban optical models are off to a strong start
  • Top Charoen deal expands the retail footprint to the high-potential market of Thailand, adding around 2k stores and bringing the Group’s network to nearly 20k locations worldwide

Paris, France (April 22, 2026 - 6:00 pm) – EssilorLuxottica announced today that consolidated revenue for the first quarter of 2026 reached Euro 7,127 million, representing a year-on-year increase of 10.8% at constant exchange rates1 compared to the first quarter of 2025 (+4.1% at current exchange rates).

Francesco Milleri, Chairman and CEO, and Paul du Saillant, Deputy CEO at EssilorLuxottica commented: “With the third consecutive quarter of double-digit growth, we once again demonstrate the strength and relevance of our strategy and our ability to deliver against it. We continued to drive robust momentum across all regions and businesses, driven by the enduring solidity of our vision care and eyewear activities and a steady pipeline of innovation.

That momentum was on full display at our global SWITCH events in Orlando and Monaco, bringing together thousands of partners and customers to showcase our transformative journey and our portfolio of life-changing solutions. It is also reflected in the continued robust traction of our myopia management platform and in the strong results delivered by wearables, fueled by the successful launch of Ray-Ban Meta’s new optical-first styles. At the same time, we continued to expand our retail footprint with our investment in Top Charoen and its 2,000-store network in Thailand, extending our world-class vision care and eye health ecosystem closer to millions more people.

We have achieved all this maintaining a strong focus on our strategy, increasingly centered on science and med-tech, supported by the dedication and resilience of our colleagues worldwide. In an uncertain environment, we move forward with clarity and confidence, shaping the future we believe in”.